Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient-derived osteosarcoma cells and synergizes with cisplatin and talazoparib.

Cells treated with the highest concentration of 100 nM showed a particulary strong and highly significant increase up to almost 20% of cells ( p ‐value: 5 nM ≤ 0.00089, 10 nM ≤ 0.045, 100 nM ≤ 0.00039).

also in 132,142 other papers